Alzheimer’s Disease Drug Development Pipeline 2020

por Sabbagh, M.N.
Publicado 2020

Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer’s Disease

por Arab, L, Sadeghi, R, Walker, D.G, Lue, L-F, Sabbagh, M.N
Publicado 2011

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

por Doraiswamy, P M, Sperling, R A, Johnson, K, Reiman, E M, Wong, T Z, Sabbagh, M N, Sadowsky, C H, Fleisher, A S, Carpenter, A, Joshi, A D, Lu, M, Grundman, M, Mintun, M A, Skovronsky, D M, Pontecorvo, M J
Publicado 2014

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis

por Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., Bittner, T., Brunton, S. A., Kerwin, D. R., Jackson, W. C., Small, G. W., Grossberg, G. T., Clevenger, C. K., Cotter, V., Stefanacci, R., Wise‐Brown, A., Sabbagh, M. N.
Publicado 2021